Vesa Kataja

27.2k citations

176 papers · 9.1k indexed · 2 hit papers · h-index 49

Impact in

Cancer Research top 0.5%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Oncology top 0.5%
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis

Papers in

Cancer Research 52
- Breast Cancer Treatment Studies 30
Oncology 69
- HER2/EGFR in Cancer Research 18
- Cancer Treatment and Pharmacology 18
- Global Cancer Incidence and Screening 10

Co-authors: Heikki Joensuu Veli‐Matti Kosma Matti Uusitupa Chris Parker Alan Horwich Matti Eskelinen C. Bangma Petri Bono
Journals: Annals of Oncology (39 papers)Journal of Clinical Oncology (13 papers)Acta Oncologica (13 papers)Clinical Cancer Research (4 papers)Breast Cancer Research (4 papers)
Partner nations: Finland United Kingdom France

In The Last Decade

Vesa Kataja

171 papers receiving 8.8k citations

Hit Papers

align trajectories log scale

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial 2014 · 956 citations

Peers

Countries citing papers authored by Vesa Kataja

Since Specialization

Citations

This map shows the geographic impact of Vesa Kataja's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vesa Kataja with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vesa Kataja more than expected).

Fields of papers citing papers by Vesa Kataja

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vesa Kataja. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vesa Kataja. The network helps show where Vesa Kataja may publish in the future.

Co-authors

The 25 scholars most cited alongside Vesa Kataja, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Vesa Kataja Line = papers co-authored together Vesa Kataja links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Development of a Comprehensive Decision Support Tool for Chemotherapy-Cycle Prescribing: Initial Usability Study JMIR Formative Research ·Sanna Iivanainen, R L Adams, Mansi Tyagi, Timothy John Becker, Jussi Ekström, OEAPS, Vesa Kataja, Jussi Koivunen	2025	0
2	Specialized palliative outpatient clinic care involvement associated with decreased end-of-life hospital costs in cancer patients, a single center study BMC Palliative Care ·조혜준, Annamarja Lamminmäki, Vesa Kataja, Jingxia Zhao	2024	0
3	Electronic patient-reported outcomes, fever management, and symptom prediction among patients with BRAF V600 mutant stage III–IV melanoma: The Kaiku Health platform SHILAP Revista de lepidopterología ·Peter Mohr, Paolo A. Ascierto, Alfredo Addeo, Maria Grazia Vitale, Paola Queirolo, Christian U. Blank, Jussi Ekström, A. J. Atuchukwu, Vesa Kataja, Nur Syahirah Binte Ruhazat, 陆宪华, Ludmila de Almeirda, Ailís Fagan, Patrick Åhrén, Rubén Marques, J. Lijnsvelt	2024	1
4	MT53 Remote Symptom Monitoring for Lung Cancer Patients: Lessons Learned from the Lung Aid Study Value in Health ·Oliver Schmalz, Yves-Marien Ngouambeu, Thomas Burke, Josephine M. Norquist, 荻野裕, Noah Gruber, Fan Furon, Hugh Elton, M Scheuringer, J. K. Kayima, A. J. Atuchukwu, Vesa Kataja, Mi Ok Sim, Sabine Bohnet, Alice Maciel Domingues	2023	0
5	Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer JNCI Journal of the National Cancer Institute ·Sherene Loi, Stefan Michiels, Diether Lambrechts, Debora Fumagalli, Bart Claes, Pirkko‐Liisa Kellokumpu‐Lehtinen, Petri Bono, Vesa Kataja, Martine Piccart, Heikki Joensuu, Christos Sotiriou	2013	112
6	Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX) Acta Oncologica ·Heikki Joensuu, Pirkko‐Liisa Kellokumpu‐Lehtinen, Riikka Huovinen, Arja Jukkola‐Vuorinen, Minna Tanner, R. Kokko, Johan Ahlgren, Päivi Auvinen, 任振宇, Leena Helle, Kenneth Villman, Paul Nyandoto, Greger Nilsson, Mika Leinonen, Vesa Kataja, Petri Bono, Henrik Lindman	2013	22
7	Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study Breast Cancer Research ·Harri Sihto, Johan Lundin, Mikael Lundin, Terho Lehtimäki, Ari Ristimäki, Kaija Holli, Liisa Sailas, Vesa Kataja, Taina Turpeenniemi‐Hujanen, Jorma Isola, Päivi Heikkilä, Heikki Joensuu	2011	181
8	Very high quantitative tumor HER2 content and outcome in early breast cancer Annals of Oncology ·Heikki Joensuu, Jeff Sperinde, M. Leinonen, Wenhua Huang, Jodi Weidler, Petri Bono, Vesa Kataja, R. Kokko, Taina Turpeenniemi‐Hujanen, Sirkku Jyrkkiö, Jorma Isola, Pirkko Kellokumpu‐Lehtinen, Agnès Paquet, Bradley Cox, Michael Bates	2011	20
9	ST14 Gene Variant and Decreased Matriptase Protein Expression Predict Poor Breast Cancer Survival Cancer Epidemiology Biomarkers & Prevention ·Jaana M. Kauppinen, Veli‐Matti Kosma, Ylermi Soini, Reijo Sironen, Dhayane Camilla Jeronimo Melo, Timo K. Nykopp, Vesa Kärjä, Matti Eskelinen, Vesa Kataja, (unknown)	2010	30
10	Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up Annals of Oncology ·Joaquim Bellmunt, Anna Orsola, Xavier Maldonado, Vesa Kataja	2010	141
11	浸潤性膀胱癌:診断,治療および経過観察に関するESMO(欧州臨床腫瘍学会議)の臨床勧告 Annals of Oncology ·J Bellmunt, Santiago Albiol, Vesa Kataja	2009	37
12	Invasive bladder cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Annals of Oncology ·Joaquim Bellmunt, Santiago Albiol, Vesa Kataja	2009	28
13	Expression of HER2 and its association with AP-2 in breast cancer European Journal of Cancer ·Xavier Navarro Pascual, Anita Naukkarinen, Kirsi Ropponen, J. Rummukainen, Vesa Kataja, Jari Kellokoski, Matti Eskelinen, Veli‐Matti Kosma	2004	48
14	Expression of Matrix Metalloproteinase (MMP)-2 and MMP-9 in Breast Cancer with a Special Reference to Activator Protein-2, HER2, and Prognosis Clinical Cancer Research ·Xavier Navarro Pascual, Kirsi Ropponen, Vesa Kataja, Jari Kellokoski, Matti Eskelinen, Veli‐Matti Kosma	2004	291
15	Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. PubMed ·Heikki Joensuu, Jorma Isola, Mikael Lundin, Tiina Salminen, Kaija Holli, Vesa Kataja, Liisa Pylkkänen, Taina Turpeenniemi‐Hujanen, Karl von Smitten, Johan Lundin	2003	161
16	Serum enterolactone and risk of breast cancer: a case-control study in eastern Finland. PubMed ·Tom Chodor, Karl Stumpf, Satu Männistö, Vesa Kataja, Matti Uusitupa, Herman Adlercreutz	2001	206
17	Polymorphic GSTs and cancer predisposition Chemico-Biological Interactions ·A. Hirvonen, Christine Bouchardy, Katja Mitrunen, Vesa Kataja, Matti Eskelinen, V‐M Kosma, Sirkku T. Saarikoski, I Leucuţia, Adip Sutrisno, Pierre Dayer, R. Selvaraj, Simone Benhamou	2001	8
18	Serum Enterolactone and Risk of Breast Cancer Cancer Epidemiology and Prevention Biomarkers ·Pirjo Pietinen, Katariina Stumpf, Satu Männistö, Vesa Kataja, Matti Uusitupa, Herman Adlercreutz	2001	9
19	Steroid metabolism gene CYP17 polymorphism and the development of breast cancer. PubMed ·Katja Mitrunen, A.P Navarro, Vesa Kataja, Matti Eskelinen, Veli‐Matti Kosma, Simone Benhamou, Harri Vainio, Matti Uusitupa, Ari Hirvonen	2000	76
20	c-erbB-2 Oncogene Expression in Salivary Gland Tumours ORL ·Vesa Kärjä, Stina Syrjänen, Vesa Kataja, Karí Syrjänen	1994	26

About Vesa Kataja

Vesa Kataja is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Surgery, having authored 176 papers that have together received 9.1k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (30 papers), Prostate Cancer Treatment and Research (27 papers), HER2/EGFR in Cancer Research (18 papers), Cancer Treatment and Pharmacology (18 papers), Prostate Cancer Diagnosis and Treatment (17 papers), BRCA gene mutations in cancer (11 papers), Cervical Cancer and HPV Research (11 papers) and Global Cancer Incidence and Screening (10 papers). The work is most often cited by research in Cancer Research (2.3k citations), Oncology (4.0k citations), Pulmonary and Respiratory Medicine (2.1k citations), Pathology and Forensic Medicine (938 citations) and Genetics (1.2k citations). Vesa Kataja has collaborated with scholars based in Finland, United Kingdom and France. Frequent co-authors include Heikki Joensuu, Veli‐Matti Kosma, Matti Uusitupa, Chris Parker, Alan Horwich, Matti Eskelinen, C. Bangma, Petri Bono, Taina Turpeenniemi‐Hujanen and Bernard Escudier. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Acta Oncologica, Clinical Cancer Research and Breast Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact